drugset
drugset / Trial / NCT01876368

Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

NCT01876368 ↗

Phase 3 Completed 376 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the efficacy and safety of LCZ696 in comparison to olmesartan in essential hypertensive patients not adequately responsive to olmesartan

Timeline

Start
2013-09
Primary completion
2014-08
Completion
2014-08

Outcome

Met primary endpoint

registry LEAST_SQUARES_MEAN LCZ696 200 mg: -4.26 (Standard Error 0.60) mmHg NCT01876368 ↗

registry analysis (superiority or other test); LCZ696 200 mg vs Olmesartan 20 mg; p <0.001; Mean Difference (Net) -3.19 (95% CI -4.73 to -1.65); ANCOVA NCT01876368 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject LCZ696 Unknown 200 mg —
Comparator Olmesartan Other / unclassified 20 mg —

Indications

essential hypertension